Market Closed -
Nasdaq
01:30:00 11/05/2024 am IST
5-day change
1st Jan Change
15.72
USD
-4.78%
-3.91%
+23.29%
Curis, Inc.(NasdaqCM:CRIS) dropped from Russell Microcap Index
June 23, 2023 at 09:30 am IST
Curis, Inc.(NasdaqCM:CRIS) dropped from Russell Microcap Index
Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
07/05
CI
Transcript : Curis, Inc., Q1 2024 Earnings Call, May 07, 2024
07/05
Earnings Flash (CRIS) CURIS Reports Q1 Revenue $2.1M, vs. Street Est of $2M
07/05
MT
HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating
09/02
MT
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
09/02
CI
Transcript : Curis, Inc., Q4 2023 Earnings Call, Feb 08, 2024
08/02
Earnings Flash (CRIS) CURIS Reports Q4 Revenue $2.7M, vs. Street Est of $3.1M
08/02
MT
Curis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
08/02
CI
Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study
12/12
CI
Curis, Inc. Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
05/12
CI
Truist Starts Curis With Buy Rating
17/11
MT
Transcript : Curis, Inc., Q3 2023 Earnings Call, Nov 02, 2023
02/11
Earnings Flash (CRIS) CURIS Posts Q3 Revenue $2.8M, vs. Street Est of $2.6M
02/11
MT
Curis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
02/11
CI
India's contaminated cough syrup cases
13/23/13
RE
Transcript : Curis, Inc., Q2 2023 Earnings Call, Aug 03, 2023
04/23/04
Earnings Flash (CRIS) CURIS Reports Q2 Revenue $2.2M, vs. Street Est of $2.5M
04/23/04
MT
Curis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
04/23/04
CI
Taseko Mines Provided Financing Update For Florence Copper
14/23/14
MT
HC Wainwright Cuts Price Target on Curis to $6 From $9, Maintains Buy Rating
07/23/07
MT
Sector Update: Health Care Stocks Softer Late Thursday
07/23/07
MT
Sector Update: Health Care Stocks Down Thursday Afternoon
06/23/06
MT
Curis Says FDA Removes Partial Clinical Hold on Emavusertib Phase 1/2 Study
06/23/06
MT
U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID
06/23/06
CI
Curis, Inc.(NasdaqCM:CRIS) dropped from Russell Microcap Index
23/23/23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
More about the company
Last Close Price
15.72
USD
Average target price
79.8
USD
Spread / Average Target
+407.63%
Consensus
1st Jan change
Capi.
+23.29% 92.66M +17.96% 44.96B +48.77% 41.85B +1.17% 42.65B -4.27% 29.04B +11.42% 26.08B -21.39% 19.03B +4.86% 12.75B +27.29% 12.06B -3.50% 11.75B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1